|
1
|
Global Burden of Disease Cancer
Collaboration, ; Fitzmaurice C, Allen C, Barber RM, Barregard L,
Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, et al:
Global, regional, and national cancer incidence, mortality, years
of life lost, years lived with disability, and disability-adjusted
life-years for 32 cancer groups, 1990 to 2015: A systematic
analysis for the global burden of disease study. JAMA Oncol.
3:524–548. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Colleoni M, Sun Z, Price KN, Karlsson P,
Forbes JF, Thürlimann B, Gianni L, Castiglione M, Gelber RD, Coates
AS and Goldhirsch A: Annual hazard rates of recurrence for breast
cancer during 24 years of follow-up: Results from the international
breast cancer study group trials I to V. J Clin Oncol. 34:927–935.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gerber B, Freund M and Reimer T: Recurrent
breast cancer: Treatment strategies for maintaining and prolonging
good quality of life. Dtsch Arztebl Int. 107:85–91. 2010.PubMed/NCBI
|
|
4
|
Dawood S, Austin L and Cristofanilli M:
Cancer stem cells: Implications for cancer therapy. Oncology
(Williston Park). 28:1101–1107, 1110. 2014.PubMed/NCBI
|
|
5
|
Palucka K and Banchereau J:
Dendritic-cell-based therapeutic cancer vaccines. Immunity.
39:38–48. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Abdullah LN and Chow EK: Mechanisms of
chemoresistance in cancer stem cells. Clin Transl Med. 2:32013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Carrasco E, Alvarez PJ, Prados J, Melguizo
C, Rama AR, Aránega A and Rodríguez-Serrano F: Cancer stem cells
and their implication in breast cancer. Eur J Clin Invest.
44:678–687. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dey P, Rathod M and De A: Targeting stem
cells in the realm of drug-resistant breast cancer. Breast Cancer
(Dove Med Press). 11:115–135. 2019.PubMed/NCBI
|
|
9
|
Islam F, Gopalan V, Smith RA and Lam AK:
Translational potential of cancer stem cells: A review of the
detection of cancer stem cells and their roles in cancer recurrence
and cancer treatment. Exp Cell Res. 335:135–147. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Britton KM, Kirby JA, Lennard TW and
Meeson AP: Cancer stem cells and side population cells in breast
cancer and metastasis. Cancers (Basel). 3:2106–2130. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Akrap N, Andersson D, Bom E, Gregersson P,
Ståhlberg A and Landberg G: Identification of distinct breast
cancer stem cell populations based on single-cell analyses of
functionally enriched stem and progenitor pools. Stem Cell Reports.
6:121–136. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shao J, Fan W, Ma B and Wu Y: Breast
cancer stem cells expressing different stem cell markers exhibit
distinct biological characteristics. Mol Med Rep. 14:4991–4998.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gelao L, Criscitiello C, Esposito A, De
Laurentiis M, Fumagalli L, Locatelli MA, Minchella I, Santangelo M,
De Placido S, Goldhirsch A and Curigliano G: Dendritic cell-based
vaccines: Clinical applications in breast cancer. Immunotherapy.
6:349–360. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Constantino J, Gomes C, Falcão A, Cruz MT
and Neves BM: Antitumor dendritic cell-based vaccines: Lessons from
20 years of clinical trials and future perspectives. Transl Res.
168:74–95. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sabado RL, Balan S and Bhardwaj N:
Dendritic cell-based immunotherapy. Cell Res. 27:74–95. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Anguille S, Smits EL, Lion E, van Tendeloo
VF and Berneman ZN: Clinical use of dendritic cells for cancer
therapy. Lancet Oncol. 15:e257–e267. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pham PV, Le HT, Vu BT, Pham VQ, Le PM,
Phan NL, Trinh NV, Nguyen HT, Nguyen ST, Nguyen TL and Phan NK:
Targeting breast cancer stem cells by dendritic cell vaccination in
humanized mice with breast tumor: Preliminary results. Onco Targets
Ther. 9:4441–4451. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Andergassen U, Vogl A, Mumm JN, Kölbl AC,
Hutter S, Rack B, Friese K and Jeschke U: Immunocytochemical
characterization of disseminated tumour cells from bone marrow of
breast cancer patients. Anticancer Res. 36:3217–3222.
2016.PubMed/NCBI
|
|
19
|
Zarif JC, Hernandez JR, Verdone JE,
Campbell SP, Drake CG and Pienta KJ: A phased strategy to
differentiate human CD14+monocytes into classically and
alternatively activated macrophages and dendritic cells.
Biotechniques. 61:33–41. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Darvin P, Sasidharan Nair V and Elkord E:
PD-L1 Expression in human breast cancer stem cells is
epigenetically regulated through posttranslational histone
modifications. J Oncol. 2019:39589082019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gao L, Guo Q, Li X, Yang X, Ni H, Wang T,
Zhao Q, Liu H, Xing Y, Xi T and Zheng L: MiR-873/PD-L1 axis
regulates the stemness of breast cancer cells. EBioMedicine.
41:395–407. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yin T, Shi P, Gou S, Shen Q and Wang C:
Dendritic cells loaded with pancreatic cancer stem cells (CSCs)
lysates induce antitumor immune killing effect in vitro. PLoS One.
9:e1145812014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xie BH, Yang JY, Li HP, Zhang B, Chen W,
Zhou B, Peng BG, Liang LJ and He Q: Dendritic cells transfected
with hepatocellular carcinoma (HCC) total RNA induce specific
immune responses against HCC in vitro and in vivo. Clin Transl
Oncol. 16:753–760. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cheever MA, Allison JP, Ferris AS, Finn
OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL,
Weiner LM and Matrisian LM: The prioritization of cancer antigens:
A national cancer institute pilot project for the acceleration of
translational research. Clin Cancer Res. 15:5323–5337. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Criscitiello C: Tumor-associated antigens
in breast cancer. Breast Care (Basel). 7:262–266. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Garg NK, Dwivedi P, Prabha P and Tyagi RK:
RNA pulsed dendritic cells: An approach for cancer immunotherapy.
Vaccine. 31:1141–1156. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
McNamara MA, Nair SK and Holl EK:
RNA-based vaccines in cancer immunotherapy. J Immunol Res.
2015:7945282015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen DS and Mellman I: Oncology meets
immunology: The cancer-immunity cycle. Immunity. 39:1–10. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bhat P, Leggatt G, Waterhouse N and Frazer
IH: Interferon-γ derived from cytotoxic lymphocytes directly
enhances their motility and cytotoxicity. Cell Death Dis.
8:e28362017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nguyen ST, Nguyen HL, Pham VQ, Nguyen GT,
Tran CD, Phan NK and Pham PV: Targeting specificity of dendritic
cells on breast cancer stem cells: In vitro and in vivo
evaluations. Onco Targets Ther. 8:323–334. 2015.PubMed/NCBI
|
|
31
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Duraiswamy J, Kaluza KM, Freeman GJ and
Coukos G: Dual blockade of PD-1 and CTLA-4 combined with tumor
vaccine effectively restores T-cell rejection function in tumors.
Cancer Res. 73:3591–3603. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zong J, Keskinov AA, Shurin GV and Shurin
MR: Tumor-derived factors modulating dendritic cell function.
Cancer Immunol Immunother. 65:821–833. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shimodaira S, Sano K, Hirabayashi K, Koya
T, Higuchi Y, Mizuno Y, Yamaoka N, Yuzawa M, Kobayashi T, Ito K and
Koizumi T: Dendritic cell-based adjuvant vaccination targeting
Wilms' tumor 1 in patients with advanced colorectal cancer.
Vaccines (Basel). 3:1004–1018. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen Y, Yao K, Wang B, Qing J and Liu G:
Potent dendritic cell vaccine loaded with latent membrane protein
2A (LMP2A). Cell Mol Immunol. 5:365–372. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hobo W, Strobbe L, Maas F, Fredrix H,
Greupink-Draaisma A, Esendam B, de Witte T, Preijers F, Levenga H,
van Rees B, et al: Immunogenicity of dendritic cells pulsed with
MAGE3, survivin and B-cell maturation antigen mRNA for vaccination
of multiple myeloma patients. Cancer Immunol Immunother.
62:1381–1392. 2013. View Article : Google Scholar : PubMed/NCBI
|
